Considering that both BET and MEK inhibitors are currently being actively evaluated for the treatment of various cancers as single agents in different stages of clinical trials (www.clinicaltrials.gov), our findings advocate a therapeutic strategy to potentially improve the efficacy by combining both agents that can disrupt the anticipated feedback activation in these tumors. The gene discussed is MAP2K7; the disease is cancer.